Latest / Community Health Media
Dr. Hope Rugo, Dr. Sarah Hurvitz, & Dr. Jennifer Tseng - T-DXd: New Curative Approvals & HER2+ Landscape
Three new approvals for trastuzumab deruxtecan (T-DXd) are reshaping the treatment landscape for HER2-positive breast cancer.
Dr. Hope Rugo, Dr. Sarah Hurvitz, and Dr. Jennifer Tseng discuss the clinical impact of DESTINY-Breast11, DESTINY-Breast05, and DESTINY-Breast09, exploring how T-DXd is changing treatment decisions across both early-stage and metastatic HER2-positive disease.
The conversation explores:
DESTINY-Breast11 and neoadjuvant T-DXd adoption
DESTINY-Breast05 and treatment after residual disease
Selecting between DB11 and DB05 strategies
Managing ILD, nausea, and T-DXd…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.